Etanidazole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Etanidazole
DrugBank Accession Number
DB12736
Background

Etanidazole has been used in trials studying the diagnostic of Adult Ependymoma, Malignant Ascites, Adult Gliosarcoma, Adult Mixed Glioma, and Adult Glioblastoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 214.181
Monoisotopic: 214.070204818
Chemical Formula
C7H10N4O4
Synonyms
  • Etanidazol
  • Etanidazole
  • Etanidazolum
External IDs
  • NSC-301467
  • SR 2508
  • SR-2508

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Etanidazole.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Etanidazole.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Etanidazole.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Etanidazole.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Radinyl

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-acylethanolamines. These are compounds containing an N-acyethanolamine moiety, which is characterized by an acyl group is linked to the nitrogen atom of ethanolamine.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
N-acylethanolamines
Alternative Parents
Nitroaromatic compounds / N-substituted imidazoles / Heteroaromatic compounds / Secondary carboxylic acid amides / Propargyl-type 1,3-dipolar organic compounds / Organic oxoazanium compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organic zwitterions
show 3 more
Substituents
Alcohol / Allyl-type 1,3-dipolar organic compound / Aromatic heteromonocyclic compound / Azacycle / Azole / C-nitro compound / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, monocarboxylic acid amide, imidazoles (CHEBI:75473)
Affected organisms
Not Available

Chemical Identifiers

UNII
30DKA3Q1HL
CAS number
22668-01-5
InChI Key
WCDWBPCFGJXFJZ-UHFFFAOYSA-N
InChI
InChI=1S/C7H10N4O4/c12-4-2-8-6(13)5-10-3-1-9-7(10)11(14)15/h1,3,12H,2,4-5H2,(H,8,13)
IUPAC Name
N-(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide
SMILES
OCCNC(=O)CN1C=CN=C1[N+]([O-])=O

References

General References
Not Available
KEGG Drug
D04075
PubChem Compound
3276
PubChem Substance
347828928
ChemSpider
3161
ChEBI
75473
ChEMBL
CHEMBL47405
ZINC
ZINC000001873938
Wikipedia
Etanidazole

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableTerminatedDiagnosticAdult Anaplastic Astrocytoma / Adult Anaplastic Ependymoma / Adult Anaplastic Oligodendroglioma / Adult Diffuse Astrocytoma / Adult Ependymoma / Adult Giant Cell Glioblastoma / Adult Mixed Glioma / Adult Myxopapillary Ependymoma / Adult Pilocytic Astrocytoma / Adult Pineal Gland Astrocytoma / Adult Subependymoma / Glioblastoma, Adult / Gliosarcoma, Adult / Oligodendroglioma, Adult1
Not AvailableTerminatedDiagnosticAscites, Malignant / Localized Malignant Mesothelioma / Mesothelioma Malignant Advanced / Primary Peritoneal Cavity Cancer / Recurrent Malignant Mesothelioma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.9 mg/mLALOGPS
logP-1.4ALOGPS
logP-1.1ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)14.28ChemAxon
pKa (Strongest Basic)0.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.29 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity48.8 m3·mol-1ChemAxon
Polarizability19.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 23:56 / Updated on February 21, 2021 18:53